Kybella is a prescription medicine used in adults to improve the appearance and profile of submental fat, obesity in the chin and neck area. Sometimes called a double chin. This procedure results with improvement in overall appearance and generally will last six to eight months depending on the amount of units injected. Maybe that extra fullness beneath your chin is something you’ve had your whole life, something that developed over the years, or something you noticed recently. Whether you have a moderate amount of fat under your chin Kybella is individually tailored, injectable, improves the chin profile and permanently destroys fat cells in the treatment area under the chin.
Before and After
Schedule A Consultation Today
Encore Medical Spa offers its clients a professional setting with board certified providers who are trained, licensed and experts in Aesthetic Medicine and facial anatomy. We also continue to enhance our practical experience with Botox, dermal fillers, laser therapy, and medical grade topical products from world renown thought leaders in Aesthetic Medicine.
Inquire with Encore Medical Spa team members to tailor treatments, topical methods and directions with how to apply, injectable methods for quick results or laser therapy to reach your goal.
Fill out the form to the right and we will be in contact with you as soon as possible.
KYBELLA® (deoxycholic acid) Important Information
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
KYBELLA® is contraindicated in the presence of infection at the injection sites.
Warnings and Precautions
Marginal Mandibular Nerve Injury — Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.
Dysphagia — Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.
Injection-Site Hematoma/Bruising — In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures — To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.
Injection Site Alopecia — Cases of injection site alopecia have been reported with administration of KYBELLA® . Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.
Injection Site Ulceration and Necrosis — Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA® . Do not administer KYBELLA® into affected area until complete resolution.
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.
Please see KYBELLA® full Prescribing Information.